Join Corbus Pharmaceuticals for an in-person and virtual investor event featuring key opinion leaders (KOLs) Ari Rosenberg, MD (UChicago Medicine), Glenn Hanna, MD (Dana-Farber Cancer Institute), and Cesar Augusto Perez Batista, MD (Sarah Cannon Research Institute), who will join company management to discuss updated dose expansion data from its Phase 1/2 clinical study of CRB-701 (SYS6002) in over 100 participants with head and neck squamous cell carcinoma (HNSCC), and cervical tumors. These data will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress 2025, held October 17-21, 2025 in Berlin, Germany.

The three-part Phase 1/2 study is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. CRB-701 is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.

A live question and answer session will follow the formal presentation.